rss
Br J Ophthalmol 2008;92:1129-1133 doi:10.1136/bjo.2007.135269
  • Original Article
    • Clinical science

The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial

  1. G S Ang1,
  2. J P Kersey1,
  3. L Shepstone2,
  4. D C Broadway1
  1. 1
    Norfolk and Norwich University Hospital, Colney Lane, Norwich, UK
  2. 2
    School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK
  1. Mr D C Broadway, Department of Ophthalmology, Norfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, UK; david.broadway{at}nnuh.nhs.uk
  • Accepted 30 March 2008
  • Published Online First 29 May 2008

Abstract

Background/aims: To determine the medium-term effect of travoprost on the daytime intraocular pressure (IOP) of patients with normal tension glaucoma (NTG)

Methods: Newly diagnosed NTG patients underwent baseline, daytime, hourly IOP phasing. Patients were randomised to either treatment or no treatment (control). Treatment comprised once daily topical travoprost 0.004%. After 6 months, the participants underwent their second IOP phasing.

Results: Data from 88 participants were analysed—54 were randomised to treatment and 34 to the control group. The mean duration of treatment was 6 months. The average, maximum and minimum diurnal IOPs for treated patients were statistically significantly lower than for control patients at follow-up (p<0.001). When compared with baseline IOP, the travoprost treated group demonstrated a decrease of 16.1%, 13.5% and 16.7% in the average IOP, maximum IOP, and minimum IOP respectively. Of those treated, about one-third achieved a decrease in average IOP of at least 20%; only about one-tenth achieved a reduction of at least 30%.

Conclusion: Travoprost monotherapy had a sustained hypotensive effect in NTG and achieved a reasonable or good response (>20% reduction in average IOP) in 32.9% of treated eyes. However, in the majority of eyes with NTG, travoprost monotherapy appeared unable to produce the desirable 30% reduction in average IOP.

Footnotes

  • Funding: The Norwich Glaucoma Research Fund, Norfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, UK.

  • Competing interests: None.

  • Ethics approval: Study approval was obtained from the Huntingdon Local Research Ethics and the East Norfolk and Waveney Research Governance committees.

  • Patient consent: Obtained.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2007.135269v1
    2. 92/8/1129 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.